Skip Navigation



Annals of Oncology Advance Access published online on November 22, 2005
Annals of Oncology, doi:10.1093/annonc/mdj074
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/5/875    most recent
mdj074v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bonneterre, M. E.
Right arrow Articles by Bonneterre, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bonneterre, M. E.
Right arrow Articles by Bonneterre, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

letter to the editor

Reply to the article "A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model based cost-effectiveness analysis", by J. Norum et al. (Ann Oncol 2005; 16: 909-914)

M. E. Bonneterre 1 and J. Bonneterre 1 *

1 Centre Oscar Lambret, 3 rue Frédéric Combemale, F-59000 Lille, France

* To whom correspondence should be addressed.
J. Bonneterre, E-mail: j-bonneterre{at}o-lambret.fr



This article has no Abstract.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.